Pediatric cancer patients vaccinated against SARS-CoV-2 —a clinical and laboratory follow-up
ConclusionsMost SARS-CoV-2-vaccinated pediatric cancer patients had SARS-CoV-2 infections and limited interest in booster vaccination. At 1 year after the last antigen exposure, which was mostly an infection, humoral immune responses remained strong.Trial registrationGerman Clinical Trials Register DRKS00025254, May 26, 2021.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | Laboratory Medicine | Pediatrics | SARS | Vaccines